Company Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib.
Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 2000 |
| IPO Date | Aug 1, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | James Dentzer |
Contact Details
Address: Building C, Suite 500 Lexington, Massachusetts 02421 United States | |
| Phone | 617 503 6500 |
| Website | curis.com |
Stock Details
| Ticker Symbol | CRIS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001108205 |
| CUSIP Number | 231269200 |
| ISIN Number | US2312693094 |
| Employer ID | 04-3505116 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| James E. Dentzer | President, Chief Executive Officer, Secretary, Treasurer and Director |
| Diantha Duvall CPA, M.B.A. | Chief Financial Officer and Principal Financial and Accounting Officer |
| Dr. Jonathan B. Zung Ph.D. | Chief Development Officer |
| Mark W. Noel | Vice President of Technology Management and Intellectual Property |
| Dr. Robert E. Martell M.D., Ph.D. | Chief Scientific Officer |
| Elif McDonald | Vice President of Investor Relations and Corporate Communications |
| Dr. Reinhard Wilhelm von Roemeling M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 30, 2024 | 424B5 | Filing |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 29, 2024 | FWP | Free Writing Prospectus |
| Aug 1, 2024 | 10-Q | Quarterly Report |
| Aug 1, 2024 | 8-K | Current Report |
| Jun 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |